Key Drivers
- Declining Liquidity
- Persistent Cash Burn
- Shareholder Dilution
AIAI Summary
COGT is a well-funded but richly valued, single-asset regulatory-commercialization bet: sequential bezuclastinib approvals could unlock multi-indication revenue, yet investors should await evidence of favorable labels and early launch uptake because approval alone may not justify expectations.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Declining Liquidity
- •Persistent Cash Burn
- •Shareholder Dilution
COGT has ample liquidity but worsening cash burn, mounting losses, dilution, and an elevated price-to-book valuation make the stock high risk.
Price Behavior
Key Price Behavior Insights:
- •Persistent Downtrend
- •Oversold Momentum
- •Failed Rebound
COGT remains in a bearish last-month downtrend, with $31.50 support at risk and rebounds likely capped below $33.20–$34.60 unless momentum improves.
Brief rebound to $33.19 was followed by a sharp drop to $31.50
Sentiment & News
Key News Insights:
- •FDA NDA acceptance
- •Deutsche Bank stake
- •Strong liquidity runway
Cogent gained institutional backing as the FDA accepted its bezuclastinib NDA, strengthening its late-2026/early-2027 regulatory outlook.
The regulatory milestone and funding runway may improve Cogent's near-term catalyst profile
Similar Companies in Healthcare
Other companies in the same sector with AI ratings